iSpecimen Strengthens Global Oncology Biospecimen Offering

Rhea-AI Summary

iSpecimen Inc. (ISPC) expands its provider network to offer researchers increased access to highly-sought-after biospecimens for oncology research, adding new suppliers, expanding existing relationships, and introducing new offerings. The expansion includes access to specimens from cancer patients in different treatment stages, with specific biomarkers and mutations, across various tissue types and biofluid formats. The company also supports liquid biopsy research and offers custom collections with increased delivery options. iSpecimen continues to utilize next generation sequencing as part of the recent cancer sequencing procurement program.

Adds New Suppliers and Expands Existing Relationships to Provide Researchers Increased Access to Highly-Sought-After Biospecimens to Advance Oncology Research

LEXINGTON, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addition of several new suppliers, expanded relationships with existing suppliers and new offerings to increase access to critically important biospecimens for advancing biomedical research in oncology.

The expansion of the provider network offers researchers access to specimens from cancer patients in different treatment stages, with specific biomarkers and mutations, across many specimen formats, including various tissue types and biofluid formats.

“Recognizing the fact that oncology research drives over 50 percent of the global demand for human biospecimens, we have been working diligently to significantly expand the iSpecimen Marketplace^® by increasing access to highly-sought-after oncology biospecimens. These specimens will be immediately available from inventory or prospectively from target patient populations across our global network of suppliers,” said Tracy Curley, iSpecimen’s CEO. “What’s more, researchers will now have access to fusion mutations and pre-screened DNA/RNA mutation characterized tumor tissue, meeting the specific demands of their research with enhanced precision and depth.”

In addition, the new offering supports liquid biopsy research, which requires a high volume of specimens from diverse patient populations. The iSpecimen Marketplace^® will also offer custom collections with peripheral blood mononuclear cells (“PBMC”) isolation, same day whole blood collection, as well as increased delivery offerings. To improve researcher accessibility to iSpecimen’s virtual inventory of pre-screened mutation characterized tumor tissue, the platform continues to utilize next generation sequencing (“NGS”) as part of the recent cancer sequencing procurement program.

About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," “believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Contacts
KCSA Strategic Communications
Phil Carlson / Erika Kay
iSpecimen@kcsa.com

Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
iSpecimen@kcsa.com

FAQ

What did iSpecimen announce?

iSpecimen Inc. (ISPC) announced the addition of new suppliers, expanded relationships with existing suppliers, and new offerings to increase access to critically important biospecimens for advancing biomedical research in oncology.

What does the expansion of the provider network offer researchers?

The expansion offers researchers access to specimens from cancer patients in different treatment stages, with specific biomarkers and mutations, across various tissue types and biofluid formats.

What specific enhancements are being made to support oncology research?

The company will offer fusion mutations and pre-screened DNA/RNA mutation characterized tumor tissue, meeting the specific demands of research with enhanced precision and depth.

What does the new offering support?

The new offering supports liquid biopsy research, which requires a high volume of specimens from diverse patient populations.

How does iSpecimen improve researcher accessibility to its virtual inventory?

To improve accessibility, the platform continues to utilize next generation sequencing as part of the recent cancer sequencing procurement program.